Botanix Pharmaceuticals has been granted a patent for a treatment regime using a topical liquid or gel with cannabidiol for dermatitis and inflammatory skin conditions. The regime involves administering between 50 mg and 3000 mg of the composition daily. GlobalData’s report on Botanix Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Botanix Pharmaceuticals Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Botanix Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Botanix Pharmaceuticals's grant share as of February 2024 was 4%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11896560B2) discloses a treatment regime for dermatitis and inflammatory skin conditions involving the administration of a topical liquid or gel composition containing cannabidiol. The regime specifies a dosage range between 50 mg and 3000 mg of the composition, with cannabidiol concentration ranging from 1% to 15% w/w. Additionally, the composition includes specific percentages of hexamethyldisiloxane, octamethyltrisiloxane, and a residual solvent that evaporates less than 5% at skin temperature over 24 hours, selected from various compounds like fatty acids, alcohols, glycols, alkanes, or ethers.

Furthermore, the patent outlines the frequency of administration (1-5 times per day), the amount of cannabidiol delivered per application (20-400 mg), and specific compositions like 4% w/w cannabidiol and 1-10% wt/wt C2-C6 alcohol. The regime aims to deliver a total daily dose of cannabidiol between 20 mg and 2000 mg for the treatment of dermatitis and atopic dermatitis. This patent provides a detailed and specific treatment protocol utilizing cannabidiol in a topical formulation for managing dermatitis and related skin conditions, offering a novel approach in the field of dermatology.

To know more about GlobalData’s detailed insights on Botanix Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies